Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C.
出版信息
Aust Prescr. 2019 Jun;42(3):108-109. doi: 10.18773/austprescr.2019.033. Epub 2019 Apr 24.
Abstract
摘要
相似文献
1
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C.索磷布韦/维帕他韦/伏西瑞韦治疗丙型肝炎
Aust Prescr. 2019 Jun;42(3):108-109. doi: 10.18773/austprescr.2019.033. Epub 2019 Apr 24.
2
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C.索磷布韦/维帕他韦/伏西瑞韦治疗丙型肝炎的概况
Infect Drug Resist. 2019 Jul 23;12:2259-2268. doi: 10.2147/IDR.S171338. eCollection 2019.
3
Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?经颈静脉肝内门体分流术：丙型肝炎患者直接抗病毒治疗失败的一个潜在危险因素？
Hepatol Commun. 2019 Mar 18;3(5):614-619. doi: 10.1002/hep4.1337. eCollection 2019 May.
4
Sofosbuvir and velpatasvir for the treatment of hepatitis C.索磷布韦和维帕他韦用于治疗丙型肝炎。
Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):501-505. doi: 10.1080/17474124.2017.1326817. Epub 2017 May 11.
5
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.索磷布韦-维帕他韦联合利巴韦林治疗 24 周用于既往直接作用抗病毒方案治疗的丙型肝炎病毒患者。
Hepatology. 2017 Oct;66(4):1083-1089. doi: 10.1002/hep.29256. Epub 2017 Aug 26.
6
Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.索磷布韦-维帕他韦：一种用于治疗所有基因型丙型肝炎感染的单片剂疗法。
Am J Health Syst Pharm. 2017 Jul 15;74(14):1045-1052. doi: 10.2146/ajhp60632.
7
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.索磷布韦/维帕他韦：首款用于丙型肝炎的泛基因型直接抗病毒联合疗法
Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1.
8
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.在肝功能损害患者中评估伏西瑞韦和索磷布韦/伏西瑞韦的药代动力学和安全性。
Clin Pharmacokinet. 2018 Nov;57(11):1449-1457. doi: 10.1007/s40262-018-0645-6.
9
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.索磷布韦/维帕他韦在初治非肝硬化基因型 1-6 型丙型肝炎病毒感染患者中的疗效：一项随机试验。
Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10.
10
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.索磷布韦和维帕他韦联合或不联合利巴韦林治疗丙型肝炎病毒相关失代偿性肝硬化的患者报告结局：来自随机、开放标签 ASTRAL-4 期 3 期试验的探索性分析。
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132. doi: 10.1016/S2468-1253(16)30009-7. Epub 2016 Aug 3.
本文引用的文献
1
Sofosbuvir with velpatasvir.索磷布韦与维帕他韦联用。
Aust Prescr. 2017 Oct;40(5):200-201. doi: 10.18773/austprescr.2017.063. Epub 2017 Aug 9.
2
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
3
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.索磷布韦、维帕他韦和沃士韦三者联用治疗慢性丙型肝炎病毒感染患者 8 周的疗效：两项 3 期随机试验。
Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.
4
Ledipasvir with sofosbuvir.来迪派韦与索磷布韦联用。
Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14.
Zotero 插件